A clinical formulation indicated for Women's Health and Oncology Support. Substance promotes estrogen suppression to regulate hormonal signaling pathways.
An aromatase inhibitor intended to manage breast cancer in postmenopausal women by alleviating tumor growth through the suppression of estrogen production.
Mechanism of Action
It blocks the enzyme aromatase, which is used to make estrogen in postmenopausal women. Since some breast cancers grow faster with estrogen, lowering its levels slows tumor progression.
Route of Administration
Oral
Onset Time
Several weeks
Duration
24 hours
Contraindications
Premenopausal status, Pregnancy, Breastfeeding, Allergy to letrozole
Severe Adverse Events
Osteoporosis (bone thinning), Bone fractures, Heart disease, Severe allergic reaction
Common Side Effects
Hot flashes, Fatigue, Joint pain, Headache
Uncommon Side Effects
Nausea, Thinning hair, High cholesterol, Increased sweating
Information for Femara is sourced from established medical standards and updated frequently. It is provided for general reference and should be confirmed with a healthcare professional before use.
